Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.50 |
| ▸ | PDE1A | P54750 | 2/20 | 0.48 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.48 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neojusticin B SCHEMBL15920775 | 0.92 | ALDH1A1 (0.72) | TOP2AKDM4EALDH1A1MAPTNPSR1 | |
| Neojusticin B SCHEMBL30471811 | 0.92 | ALDH1A1 (0.72) | TOP2AKDM4EALDH1A1MAPTNPSR1 | |
| Neojusticin B SCHEMBL30190318 | 0.92 | ALDH1A1 (0.72) | TOP2AKDM4EALDH1A1MAPTNPSR1 | |
| Chinensinaphthol Methyl Ether SCHEMBL30471865 | 0.91 | KDM4E (0.70) | TOP2AKDM4EALDH1A1MAPTNPSR1 | |
| Chinensinaphthol Methyl Ether SCHEMBL30471940 | 0.91 | KDM4E (0.70) | TOP2AKDM4EALDH1A1MAPTNPSR1 | |
| Neojusticin A SCHEMBL15624855 | 0.89 | MAPT (0.65) | TOP2AKDM4EALDH1A1MAPTNPSR1 | |
| Neojusticin A SCHEMBL30637475 | 0.89 | MAPT (0.65) | TOP2AKDM4EALDH1A1MAPTNPSR1 | |
| SCHEMBL17280386 | 0.85 | ALDH1A1 (0.60) | TOP2AKDM4EALDH1A1MAPTNPSR1 | |
| Cilinaphthalide B SCHEMBL15920690 | 0.83 | MAPT (0.63) | TOP2AKDM4EALDH1A1MAPTNPSR1 | |
| SCHEMBL4096679 | 0.83 | KDM4E (0.85) | TOP2AKDM4EALDH1A1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2037913-B1 | TREATMENT OF ERECTILE DYSFUNCTION AND LIBIDO ENHANCEMENT | CSIR (ZA) | 2016-07-20 | — | — | EP | claimed |
| US-8609151-B2 | Treatment of erectile dysfunction and libido enhancement | CSIR (ZA) | 2013-12-17 | — | — | US | claimed |
| US-20090202662-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND LIBIDO ENHANCEMENT | CSIR (ZA) | 2009-08-13 | — | — | US | claimed |
| EP-2037913-B1 | TREATMENT OF ERECTILE DYSFUNCTION AND LIBIDO ENHANCEMENT | CSIR (ZA) | 2016-07-20 | — | — | EP | disclosed |
| EP-2037913-B1 | TREATMENT OF ERECTILE DYSFUNCTION AND LIBIDO ENHANCEMENT | CSIR (ZA) | 2016-07-20 | — | — | EP | disclosed |
| US-9211278-B2 | Composition containing arylnaphthalene lignan derivative for preventing and/or treating dementia | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-12-15 | — | — | US | disclosed |
| US-9211278-B2 | Composition containing arylnaphthalene lignan derivative for preventing and/or treating dementia | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-12-15 | — | — | US | disclosed |
| US-20140088186-A1 | COMPOSITION CONTAINING ARYLNAPHTHALENE LIGNAN DERIVATIVE FOR PREVENTING AND/OR TREATING DEMENTIA | THE COUNCIL FOR SCIENTIFIC AND INDUSTRIAL RESEARCH (ZA) | 2014-03-27 | — | — | US | disclosed |
| US-20140088186-A1 | COMPOSITION CONTAINING ARYLNAPHTHALENE LIGNAN DERIVATIVE FOR PREVENTING AND/OR TREATING DEMENTIA | THE COUNCIL FOR SCIENTIFIC AND INDUSTRIAL RESEARCH (ZA) | 2014-03-27 | — | — | US | disclosed |
| US-8609151-B2 | Treatment of erectile dysfunction and libido enhancement | CSIR (ZA) | 2013-12-17 | — | — | US | disclosed |
| US-20090202662-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND LIBIDO ENHANCEMENT | CSIR (ZA) | 2009-08-13 | — | — | US | disclosed |
| US-20090202662-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND LIBIDO ENHANCEMENT | CSIR (ZA) | 2009-08-13 | — | — | US | disclosed |
| US-20090202662-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND LIBIDO ENHANCEMENT | CSIR (ZA) | 2009-08-13 | — | — | US | disclosed |
| WO-2007138531-A2 | TREATMENT OF ERECTILE DYSFUNCTION AND LIBIDO ENHANCEMENT | CSIR (ZA) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088186-A1 | COMPOSITION CONTAINING ARYLNAPHTHALENE LIGNAN DERIVATIVE FOR PREVENTING AND/OR TREATING DEMENTIA | PSEN2, PSEN1, SORT1 | TOP2A 2500/4885KDM4E 1619/4885ALDH1A1 1896/4885 |
| US-20090202662-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND LIBIDO ENHANCEMENT | PDE3A, PDE2A, PDE3B | TOP2A 1729/4885KDM4E 2993/4885ALDH1A1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.